Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Waystar is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-08-07SCHEDULE 13G/A
- 10-Q2026-07-29Quarterly report
- 8-K2026-07-29Current report (material event)
- 8-K2026-06-04Current report (material event)
- 10-Q2026-04-29Quarterly report
- 8-K2026-04-29Current report (material event)
- DEFA14A2026-04-17DEFA14A
- DEF 14A2026-04-17Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 10-K2026-02-17Annual report
- 8-K2026-02-17Current report (material event)
- 8-K2026-02-06Current report (material event)
- SCHEDULE 13G2026-02-05SCHEDULE 13G
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-11-13SCHEDULE 13G/A
- SCHEDULE 13G/A2025-11-07SCHEDULE 13G/A
- SCHEDULE 13G/A2025-10-31SCHEDULE 13G/A
- 10-Q2025-10-29Quarterly report
- 8-K2025-10-29Current report (material event)
- SCHEDULE 13G2025-10-17SCHEDULE 13G
- D2025-10-10D
- SCHEDULE 13D2025-10-03SCHEDULE 13D
- 8-K2025-10-01Current report (material event)
- 8-K2025-09-11Current report (material event)
- 424B72025-09-11424B7
- FWP2025-09-10FWP
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- 8-K2025-08-12Current report (material event)
- SCHEDULE 13G/A2025-08-08SCHEDULE 13G/A
- 10-Q2025-07-30Quarterly report
- 8-K2025-07-30Current report (material event)
- SCHEDULE 13G2025-07-29SCHEDULE 13G
- 8-K2025-07-23Current report (material event)
- S-3ASR2025-07-14S-3ASR
- 8-K2025-06-05Current report (material event)
- 424B72025-05-15424B7
- SCHEDULE 13G/A2025-05-15SCHEDULE 13G/A
- EFFECT2025-05-14EFFECT
- CORRESP2025-05-13CORRESP
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.